Clinical trials: Anlotinib
Biliary Tract Cancer, Second Line Treatment
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Biliary tract cancer (BTC) presents with a 5-year survival rate less than 5%. The goal of this clinical trial is to evaluate if Anlotinib plus Nab-Paclitaxels and S-1 as second-line regimen can improve the treatment efficacy in…
- Conditions
- Biliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase Inhibitor
- Trial name
- NCT06662877
- Testing
- Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib, Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer, Brain Metastases
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Subject population：Patients with brain metastases from EGFR mutation-positive non-small cell lung cancer who have not received systemic treatment. Experimental design: Single-center, single-arm phase II clinical trial.
- Trial name
- NCT04978753
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Li-kun Chen
SCLC, Extensive Stage
Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment
This single-arm phase II study aims to evaluate the efficacy and safety of lomustine combined with anlotinib in patients with extensive-stage small cell lung cancer resistant to second-line and above systemic treatment.
- Trial name
- Aurora003 (NCT07632209)
- Testing
- Lomustine, Anlotinib
- Volunteers
- 46 people
- Sponsor
- Yayi He
Gastric Cancer
Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer
An exploratory study of pembrolizumab combined with anlotinib and chemotherapy in the perioperative treatment of locally advanced gastric cancer
- Trial name
- ICTCPTLAGC (NCT05385900)
- Testing
- Penpulimab combination with anlotinib and chemotherapy
- Volunteers
- 57 people
- Sponsor
- Xijing Hospital
Medullary Thyroid Cancer
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
- Trial name
- NCT05830500
- Testing
- Anlotinib Hydrochloride Capsule
- Where
- 19 sites in China
- Volunteers
- 360 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Esophageal Cancer
Anlotinib for Esophageal Cancer (AFEC)
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the…
- Trial name
- NCT04966611
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Anyang Tumor Hospital
HER2-Negative Breast Cancer
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
Angiogenesis inhibition represents a significant therapeutic target in breast cancer; however, despite its theoretical feasibility, progress in advanced breast cancer has been slow.
- Trial name
- NCT07396454
- Testing
- Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Extensive Stage Small Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of tislelizumab combined with Anlotinib as maintenance therapy following tislelizumab and chemotherapy for treatment naïve extensive…
- Trial name
- NCT05896059
- Testing
- Tislelizumab, Anlotinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Zhejiang Cancer Hospital
NSCLC
A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer
The study will evaluate the efficacy and safety of treatment with sunvozertinib in combination with Anlotinib in patients whose disease has progressed following first-line EGFR-TKIs treatment.
- Trial name
- WUKONG-9 (NCT06182761)
- Testing
- Sunvozertinib combination with Anlotinib
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Colorectal Cancer
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
This is an exploratory, non-controlled, multi-cohort, phase II small-sample clinical study designed to evaluate the clinical benefit of second-line treatment with anlotinib plus irinotecan or further in combination with a PD-1…
- Trial name
- NCT05229003
- Testing
- Anlotinib, Penpulimab, Irinotecan
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University
Aumolertinib, Anlotinib
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
The goal of this open, single-arm, exploratory phase II clinical study is to exploratory safety and efficacy in 1st line treatment in advanced lung cancer EGFR mutation with TP53 co-mutation.
- Conditions
- Aumolertinib, Anlotinib, TP53, NSCLC
- Trial name
- NCT05778149
- Testing
- Aumolertinib,Anlotinib
- Volunteers
- 47 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Small Cell Lung Carcinoma
A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
This is a prospective, randomized, open-label and active controlled phase II study. It plans to enroll 60 subjects with extensive stage small cell lung cancer (ES-SCLC).
- Trial name
- NCT03700359
- Testing
- Anlotinib Hydrochloride, Lobaplatin, Etoposide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Advanced Colorectal Cancer
Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer
1. Determine the maximum tolerable dose (MTD) and / or phase II recommended dose (RP2D) of the allotinib combined mXELIRI protocol. 2.
- Trial name
- NCT05035914
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Advanced Cancer
A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- ALTN (NCT01833923)
- Testing
- anlotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Colorectal Cancer
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
This is an open label, randomized, phase Ⅲ study to treat subjects with RAS/BRAF wild-type, unresectable metastatic colorectal cancer.
- Trial name
- NCT04854668
- Testing
- Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin
- Where
- 92 sites in China
- Volunteers
- 748 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
The investigators hypothesize that combination anlotinib with toripalimab will improve progression-free survival relative to historical controls in patients with Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma.
- Trial name
- NCT03946943
- Testing
- Anlotinib, Toripalimab, Blood Draw
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Di Wu
Relapsed Small Cell Lung Cancer, Anlotinib
A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer
Anlotinib hydrochloride is a multi-target antiangiogenic drug. It was recommended by Chinese Society of Clinical Oncology(CSCO) guideline as a third-line treatment for advanced small-cell lung cancer.
- Trial name
- NCT04757779
- Testing
- anlotinib hydrochloride combined with irinotecan or docetaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- First People's Hospital of Hangzhou
Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
PARP inhibitors have changed the treatment paradigm of ovarian cancer. Most patients using PARP(poly-ADP ribose polymerase) inhibitors will suffer different grades of adverse events(AEs), followed by dose reduction.
- Conditions
- Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- ANLOLA (NCT04566952)
- Testing
- Anlotinib, Olaparib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Xiaoxiang Chen
Metastatic Nasopharyngeal Carcinoma
Metastatic Nasopharyngeal Carcinoma
To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.
- Trial name
- NCT06886347
- Testing
- Penplimab Injection, Antitinib Hydrochloride Capsules, Gemcitabine
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Chen Xiaozhong
SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Lung Cancer
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
The goal of this clinical trial is to evaluate the efficacy and safety of combining Anlotinib with platinum-based chemotherapy for treating locally advanced or advanced lung cancer in patients whose tumors are characterized by…
- Trial name
- NCT07307443
- Testing
- Anlotinib, nab-paclitaxel, carboplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Zhijie Wang